1. Home
  2. NWAX vs YDES Comparison

NWAX vs YDES Comparison

Compare NWAX & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New America Acquisition I Corp. Class A Common Stock

NWAX

New America Acquisition I Corp. Class A Common Stock

N/A

Current Price

$10.06

Market Cap

499.5M

Sector

Finance

ML Signal

N/A

Logo YD Bio Limited Ordinary Shares

YDES

YD Bio Limited Ordinary Shares

N/A

Current Price

$5.00

Market Cap

422.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NWAX
YDES
Founded
2025
2013
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
499.5M
422.9M
IPO Year
2025
2024

Fundamental Metrics

Financial Performance
Metric
NWAX
YDES
Price
$10.06
$5.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 219.7K
102.6K
Earning Date
01-01-0001
08-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.68
$1.70
52 Week High
$10.34
$15.72

Technical Indicators

Market Signals
Indicator
NWAX
YDES
Relative Strength Index (RSI) 61.39 42.35
Support Level $10.06 $4.69
Resistance Level $10.09 $5.15
Average True Range (ATR) 0.02 0.82
MACD 0.01 -0.16
Stochastic Oscillator 100.00 0.00

Price Performance

Historical Comparison
NWAX
YDES

About NWAX New America Acquisition I Corp. Class A Common Stock

New America Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to throughout this prospectus as its initial Business Combination.

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.

Share on Social Networks: